Please check your internet connection and try again.
# Mylodermat (Mylod)
## Overview
Mylodermat (commonly referred to as **Mylod**) is a topical formulation typically containing a corticosteroid (often betamethasone dipropionate) sometimes combined with an antifungal or antibacterial agent, depending on the specific regional branding. **Note:** As "Mylod" is a brand name used for various combination products in different international markets, ensure the specific active ingredients are verified on the product packaging before use.
## Primary Indications
Used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly when complicated by secondary bacterial or fungal infections (e.g., eczema, contact dermatitis, psoriasis, or infected dermatophytoses).
## Adult Dosing
Apply a thin layer to the affected skin area twice daily (every 12 hours).
* **Maximum Duration:** Limit to 2 weeks of continuous use to minimize risks of skin atrophy and systemic absorption.
* **Total Quantity:** Do not exceed 45–50 grams per week.
## Pediatric Dosing
Use is generally discouraged in children under 12 years. If necessary, use the lowest effective dose for the shortest duration possible.
* **Dosing:** Apply a thin layer to the affected area once or twice daily.
* **Caution:** Pediatric patients have a higher surface-area-to-weight ratio, increasing the risk of systemic corticosteroid absorption, HPA axis suppression, and Cushing’s syndrome.
## Dose Adjustments
* **Geriatric:** Use with caution; elderly skin is more prone to atrophy.
* **Hepatic/Renal Impairment:** No formal adjustments established; however, monitor for systemic absorption if applying to large surface areas or under occlusive dressings.
## Contraindications
* Hypersensitivity to any component (corticosteroids, aminoglycosides, or antifungals in the specific formulation).
* Presence of tuberculosis of the skin, viral infections (e.g., herpes simplex, varicella), or fungal infections not covered by the specific included antifungal.
* Application to the face, groin, or axillae (risk of striae and atrophy).
* Use in or around the eyes (risk of glaucoma/cataracts).
## Adverse Effects
* **Local:** Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis.
* **Systemic (with prolonged use or occlusion):** HPA axis suppression, Cushing’s syndrome, hyperglycemia, and glycosuria.
## Key Drug Interactions
* **Systemic Corticosteroids:** Additive risk of HPA axis suppression if used concurrently.
* **Topical Agents/Cosmetics:** May delay absorption or alter the vehicle integrity if applied simultaneously.
## Monitoring
* Monitor for signs of local skin atrophy (thinning), striae, or telangiectasia.
* Assess for secondary infection if the inflammatory condition worsens.
* If used long-term, consider periodic HPA axis assessment (e.g., ACTH stimulation test, morning serum cortisol).
## Clinical Pearls
* **Occlusion:** Do not use under occlusive dressings (e.g., plastic wrap, tight diapers) unless directed by a physician, as this significantly increases systemic absorption and toxicity risk.
* **Application:** Apply sparingly; "fingertip units" should be used to gauge appropriate application.
* **Discontinuation:** If irritation or sensitization develops, discontinue use immediately.
* **Protocol:** Local institutional practice may vary significantly; always consult local hospital pharmacy guidelines for specific formulation requirements.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the official package insert, local prescribing guidelines, or a licensed pharmacist/physician to verify current information before prescribing or administering any medication.
